← All stories

WHO’s Adult Type 1 Diabetes Guidelines, Explained

An insulin vial, syringe, glucose meter, and world map symbolize practical type 1 diabetes care across different settings.

The World Health Organization published its adult type 1 diabetes guideline on 12 November 2026, followed by a World Diabetes Day announcement on 14 November. Its central priority is practical: make effective insulin treatment and glucose monitoring accessible across health systems, including where resources or services are disrupted.

For someone living with type 1 diabetes, the useful questions are how these recommendations relate to their existing care, which decisions need individual assessment, and what the document leaves outside its scope. This explainer examines those questions using the full guideline.

Who the guideline is for

The guidance applies to adults aged 18 and over. Its main audience is healthcare professionals, with relevance for policymakers and organizations delivering care in emergencies. It excludes pregnancy, children, insulin pumps and automated insulin delivery, as well as the clinical management of acute and established long-term complications. See the guideline’s scope, p. xiii.

This scope helps explain its priorities. A recommendation intended for clinics with reliable supplies and specialist support must also be considered in places where access is fragile. For readers, the distinction matters: a global guideline provides a framework that a care team adapts to the person and the setting.

The main recommendations, explained

Insulin treatment needs monitoring and education

WHO strongly recommends intensified insulin therapy: multiple daily injections, adjusted using blood glucose information. Its separate recommendation for emergency and humanitarian settings is conditional, reflecting the need to adapt care to available resources and support. This usually combines background, or basal, insulin with mealtime, or bolus, insulin. Education and access to monitoring are part of using that approach safely. WHO recommendations 2a and 2b, p. 25. Dose adjustments should follow a plan agreed with a healthcare professional. WHO recommendation 9, remarks, p. 62.

The guideline allows human insulin and insulin analogues, with human insulin generally preferred because it costs less. That is a population-level access consideration. An individual’s choice also involves clinical needs and whether the treatment can be obtained consistently. The announcement alone is not a reason to replace an established prescription. WHO guideline overview.

HbA1c and everyday glucose readings answer different questions

HbA1c is a blood test used to assess average glucose over the preceding months. WHO recommends testing at intervals of up to three months and a target of 7% or lower (53 mmol/mol) for most adults. The frequency is flexible, and the target may be individualized according to hypoglycemia risk, other illnesses and personal circumstances. WHO recommendations 7 and 8, pp. 56–59.

HbA1c does not reveal the full pattern of glucose swings or low-glucose episodes. The 2026 ADA/EASD consensus, section 7, therefore emphasizes interpreting it alongside other glucose information. A useful question at an appointment is whether the average result and the daily readings tell the same story.

WHO includes fingerstick testing and continuous glucose monitoring (CGM) among self-monitoring options. CGM uses a sensor to follow glucose trends. The practical purpose of monitoring is to support safe decisions between appointments; a periodic HbA1c test serves a different role. WHO’s monitoring summary.

An uncertain diagnosis needs clinical assessment

Type 1 diabetes can develop in adulthood and may be mistaken for type 2. When the diagnosis is uncertain, WHO advises considering islet autoantibodies and C-peptide testing. WHO recommendation 1, p. 21. Autoantibodies can help identify an autoimmune process; C-peptide provides information about the body’s own insulin production. Results need clinical interpretation. ADA/EASD 2026, section 2.

WHO explicitly says that biomarker testing should not delay insulin when it is clinically indicated. Someone with suspected diabetes needs prompt medical assessment rather than waiting to arrange a particular test independently. WHO recommendation 1, p. 21.

When to seek urgent help: Diabetic ketoacidosis (DKA) needs emergency treatment. Seek emergency care if you suspect DKA, especially when thirst and frequent urination occur with vomiting, deep breathing, fruity-smelling breath, drowsiness or confusion. It can occur before diabetes has been diagnosed. NHS: diabetic ketoacidosis.

Why the strength of a recommendation matters

The guideline contains one strong recommendation and 13 conditional recommendations. A conditional recommendation allows greater room for individual circumstances, resources and preferences. Its importance cannot be judged from that label alone. WHO summary, p. xiv.

The evidence also has limits. For the comparison of intensified and conventional insulin regimens, WHO describes four small trials conducted between 1986 and 1996, none in humanitarian settings. The document’s research-gaps section identifies limited representation from lower-resource settings and incomplete evidence on some longer-term outcomes. Evidence summary, pp. 26–27; research gaps, p. 79.

Our interpretation is that readers should distinguish confidence in a broad care principle from certainty about every outcome in every setting. The useful follow-up question is how the recommendation fits the person’s circumstances and available support.

How this fits with the 2026 ADA/EASD consensus

The American Diabetes Association and European Association for the Study of Diabetes published an updated adult type 1 diabetes consensus in September 2026. It addresses technologies that the WHO guideline places outside its scope. Automated insulin delivery links a glucose sensor, pump and control software to adjust insulin delivery, while still requiring user input.

Topic How to read the two documents together
Glucose monitoring WHO includes fingerstick testing and CGM. ADA/EASD favors CGM as the preferred monitoring method.
Pumps and automation WHO excludes these from its scope. ADA/EASD identifies automated insulin delivery as the optimal delivery approach when used consistently.
The individual decision Technology choices still need to account for the person’s circumstances, preferences and support.
Editorial comparison of the WHO guideline and the ADA/EASD 2026 consensus, section 7. Read the consensus.

For someone already using a pump, WHO’s emphasis on injections is not an instruction to stop pump therapy. The difference in scope is essential to understanding the headlines. Treatment changes belong in a discussion with the diabetes care team.

Questions to take to your next appointment

The most useful next step is to connect the guidance to the care plan you already have. These questions can help organize that conversation:

  • Is my HbA1c target appropriate for my risk of low glucose and my other health needs?
  • What do my daily readings show that my HbA1c result does not?
  • Would a different monitoring or insulin-delivery option address a specific problem I am experiencing?
  • Do I have a clear plan for illness, supply interruptions and when to seek urgent help?

Keep following your agreed treatment plan while arranging that discussion. Do not start, stop or switch insulin because of a news article.

Sources and preparation

Updated 15 November 2026. AI tools assisted with drafting and comparison of claims against the sources below, including the full WHO guideline. The explanations and comparison table are editorial synthesis. This revision has not been medically reviewed by a clinician. It provides general information and does not replace advice from your diabetes care team.

  1. WHO: Guidelines on insulin use for type 1 diabetes in adults, including in emergency and humanitarian settings. Published 12 November 2026. Full guideline PDF.
  2. WHO: announcement of the adult type 1 diabetes guidelines. Published 14 November 2026.
  3. Holt and colleagues: The management of type 1 diabetes in adults — updated ADA/EASD consensus report. Diabetologia, published 16 September 2026; updated version consulted.
  4. NHS: Diabetic ketoacidosis. Accessed 15 November 2026.
Explore more stories →
Written by

Gregor Ionesco

Gregor Ionesco is the editor of Stellar Cubes, where he oversees coverage of longevity, sleep, nutrition, fitness and health technology. He works with research-led editorial workflows, checks sources and framing before publication, and is the contact for corrections and editorial questions. He is not a medical professional, and Stellar Cubes articles are informational rather than personal medical advice.

About Stellar Cubes and our editorial approach →

Leave a Reply

Your email address will not be published. Required fields are marked *